GC021109

GC021109 is an orally bioavailable small molecule prodrug developed as a disease-modifying therapy for Alzheimer's disease. It acts as an agonist of the purinergic P2Y6 receptor, a metabotropic G-protein coupled receptor primarily expressed on microglial cells in the central nervous system. Activation of P2Y6 by GC021109 is reported to stimulate microglial phagocytosis and inhibit the release of pro-inflammatory cytokines such as IL-12, potentially shifting microglia from a patrolling to a phagocytic phenotype. This dual action aims to promote clearance of amyloid plaques and reduce neuroinflammation—two key pathological features in Alzheimer’s disease. Preclinical studies have also shown efficacy in models of asthma, suggesting anti-inflammatory effects beyond neurodegeneration. The drug has completed Phase 1 clinical trials evaluating safety, tolerability, and pharmacokinetics in both healthy volunteers and patients with mild-to-moderate Alzheimer’s disease[1][2][3][4][5][6][7].